Press Releases

Nov 24, 2020

PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Colorectal Surgery

PETAH TIKVA, Israel , Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX 100 has
Read More >
Nov 11, 2020

PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results

•  Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100   in a bdominal s urgery   have r eceived IRB approval   •  Phase 3 SHIELD II t rial a dvanced ; preparations   underway to i nitiate by y ear-end 2020 •  Conference Call S cheduled for t oday at 8:30 a . m .
Read More >
Nov 04, 2020

PolyPid to Participate in Three Upcoming Investor Conferences

PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will present
Read More >
Oct 28, 2020

PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020

PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report
Read More >
Aug 19, 2020

PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Initiated Phase 3 SHIELD I Trial for D-PLEX 100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX 100   from FDA Presented Positive Phase 2 Results of D-PLEX 100 for Prevention of Surgical Site Infections in Abdominal Surgery at ASCRS Meeting Completed Initial Public Offering in
Read More >
Aug 05, 2020

PolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020

PETAH TIKVA, Israel , Aug. 05, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report
Read More >
Aug 03, 2020

PolyPid Granted Fast Track Designation from FDA for D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

PETAH TIKVA, Israel , Aug. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX 100 has
Read More >
Jul 27, 2020

PolyPid to Present Phase 2 Results of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions

PETAH TIKVA, Israel , July 27, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that Dr.
Read More >
Jul 01, 2020

PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections

Petah Tikva, Israel – July 1 st , 2020 –  PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical- stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been
Read More >
Jun 30, 2020

PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Petah Tikva, Israel – June 30, 2020 – PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage pharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, announced the closing of its initial public offering of
Read More >
Displaying 1 - 10 of 12

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >